NTLA Intellia Therapeutics
- 25.150
- -0.810-3.12%
- 25.220
- +0.070+0.28%
Intellia Therapeutics News
Express News | Intellia Therapeutics Names Brian Goff to Its Board of Directors
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $60
RBC Capital analyst Luca Issi maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 20.3% an
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
On Thursday, Cathie Wood-led Ark Invest made significant trades in Amazon.com Inc (NASDAQ:AMZN) and Reddit Inc (NYSE:RDDT), amidst notable developments in both companies.The Amazon.com Trade: Ark Inve
It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put Under The Microscope
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics
In the last three months, 4 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), offering a diverse range of perspectives from bullish to bearish.The following table summarizes thei
Intellia Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 179.93% Cantor Fitzgerald $65 → $65 Reiterates Overweight → Overweight 05/10/2024 24.89% Citigr
Cantor Fitzgerald Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald analyst Rick Bienkowski maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $65 to $95
On Jun 04, major Wall Street analysts update their ratings for $Intellia Therapeutics(NTLA.US)$, with price targets ranging from $65 to $95.BofA Securities analyst Greg Harrison maintains with a buy r
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
Why Intellia Therapeutics Shares Are Trading Higher Monday
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is moving higher Monday after the company announced long-term data from its Phase 1 Study of NTLA-2002.The Details: Intellia's NTLA-2002 is an experimen
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Intellia Rallies on Phase 1 Data for CRISPR-based HAE Therapy
Market-Moving News for June 3rd
GME: 103% | 'Roaring Kitty' Reveals Massive GME Position On Reddit, Including $65M Call Options: Is He Bringing 'Courage' Back To Wall Street?BPTH: 81% | Bio-Path Presented Interim Results From Phase
Express News | Intellia Therapeutics Shares Are Trading Higher After the Company Announced Long-term Data From the Phase 1 Portion of the Ongoing Phase 1/2 Study of NTLA-2002
Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Intellia Therapeutics (NTLA) said Sunday that it observed a 98% mean reduction in monthly attack rate in the phase 1 portion of its ongoing phase 1/2 study of NTLA-2002.
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
Intellia Therapeutics Announced Single Dose Of Ntla-2002 Led To A 98% Mean Reduction In Monthly Hereditary Angioedema Attack Rate, With An Average Follow-up Of Over 20 Months Across All Patients
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phas
Express News | Intellia Therapeutics Announces Positive Long-Term Data From Ongoing Phase 1 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (Hae)
Intellia Therapeutics Announces Positive Long-Term Data From Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.
Analysis
Price Target
No Data
